SCHEMBL2834708

SCHEMBL2834708

Cc1ccc(-c2cc(C#N)c(Cl)nc2-c2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.68
CYP1A2 P05177 3/20 0.68
CYP2C9 P11712 3/20 0.68
CYP2C19 P33261 3/20 0.68
CNR1 P21554 2/20 0.52
ADORA1 P30542 4/20 0.49
ADORA2A P29274 3/20 0.49
KDM4E B2RXH2 4/20 0.48
HPGD P15428 3/20 0.48
PPARG P37231 1/20 0.48
NCOA2 Q15596 1/20 0.48
NCOA1 Q15788 1/20 0.48
NCOA3 Q9Y6Q9 1/20 0.48
ADORA2B P29275 1/20 0.47
AKT1 P31749 1/20 0.46
AKT2 P31751 1/20 0.46
ALDH1A1 P00352 6/20 0.46
TDP1 Q9NUW8 4/20 0.46
CDK1 P06493 1/20 0.45
KDR P35968 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1939380 1.00 NPSR1 (0.68) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL13498508 0.91 NPSR1 (0.69) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL14272626 0.86 NPSR1 (0.49) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL2832926 0.83 ADORA1 (0.49) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL13800046 0.83 ADORA1 (0.49) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL1939347 0.83 NPSR1 (0.56) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL19835709 0.82 CNR1 (0.55) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL7284448 0.81 NPSR1 (1.00) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL29904596 0.81 NPSR1 (1.00) NPSR1CYP1A2CYP2C9CYP2C19CNR1
SCHEMBL14532195 0.80 CNR1 (0.46) NPSR1CYP1A2CYP2C9CYP2C19CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728014-B2 Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity ALLERGAN, INC. 2010-06-01 US disclosed
US-7728014-B2 Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity ALLERGAN, INC. 2010-06-01 US disclosed
US-7728014-B2 Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity ALLERGAN, INC. 2010-06-01 US disclosed
EP-2064183-A2 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY Allergan, Inc. (US) 2009-06-03 EP disclosed
WO-2008030838-A2 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2008-03-13 WO disclosed
US-20080064872-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. 2008-03-13 US disclosed
US-20080064872-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. 2008-03-13 US disclosed
US-20080064872-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064872-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY S1PR4, S1PR3, S1PR1 NPSR1 48/4885CYP1A2 1133/4885CYP2C9 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.